読み込み中
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
最新データ
$471.75
−$5.16 · -1.08%
日中の時刻はETです。市場データは遅延する場合があります。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
93
大幅な割安
センチメント
55
まちまち
リスク
33
中程度のリスク
モメンタム
60
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 9.58億 USD | 1.8億 USD | — | — | — |
| 売上原価 | 5614.8万 USD | 623.3万 USD | — | — | — |
| 粗利益 | 9.02億 USD | 1.74億 USD | — | — | — |
| 研究開発 | 3.89億 USD | 2.37億 USD | 2.72億 USD | 2.45億 USD | 2.05億 USD |
| 販売・一般管理 | 8.14億 USD | 4.35億 USD | 1.08億 USD | 4813万 USD | 3731.8万 USD |
| 営業費用 | 12.02億 USD | 6.72億 USD | 3.8億 USD | 2.94億 USD | 2.42億 USD |
| 受取利息 | 3736.4万 USD | 4665.4万 USD | 1957.8万 USD | 218.5万 USD | 36.3万 USD |
| 支払利息 | 2230.9万 USD | 1467.1万 USD | 1271.2万 USD | 396.4万 USD | — |
| 減価償却費と償却費 | 150.6万 USD | 109.6万 USD | 52.7万 USD | 46.7万 USD | 40.5万 USD |
| 営業利益 | −3億 USD | −4.98億 USD | −3.8億 USD | −2.94億 USD | −2.42億 USD |
| 純利益 | −2.88億 USD | −4.66億 USD | −3.74億 USD | −2.95億 USD | −2.42億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2016年7月25日 | 1:35 | — | — |
発効済み 2016年7月25日
1:35
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3.17億0.01%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.29億0.12%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.32億0.29%447億 USD0.05%$344.74+1.22%
State Street SPDR S&P Biotech ETFXBI1.31億1.32%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF1.19億0.12%954億 USD0.05%$235+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT7957.9万2.75%28.91億 USD0.55%$265.4+2.00%
iShares Biotechnology ETFIBB7953.09万0.76%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA5024.23万0.23%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
